JP5441269B2 - ビシクロ置換ピラゾロン−アゾ誘導体、その調製プロセス及び製薬学的使用 - Google Patents
ビシクロ置換ピラゾロン−アゾ誘導体、その調製プロセス及び製薬学的使用 Download PDFInfo
- Publication number
- JP5441269B2 JP5441269B2 JP2010541680A JP2010541680A JP5441269B2 JP 5441269 B2 JP5441269 B2 JP 5441269B2 JP 2010541680 A JP2010541680 A JP 2010541680A JP 2010541680 A JP2010541680 A JP 2010541680A JP 5441269 B2 JP5441269 B2 JP 5441269B2
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- mmol
- carboxylic acid
- methyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc(c(*)c1N)c(*)c(*)c1O* Chemical compound Cc(c(*)c1N)c(*)c(*)c1O* 0.000 description 5
- KRZYNXDIKJPGSW-QYQHSDTDSA-N CC(/C(/C1=O)=N/Nc(cc(C)cc2-c3ccc(C(O)=O)[o]3)c2O)=NN1c1cc(CCC2)c2cc1 Chemical compound CC(/C(/C1=O)=N/Nc(cc(C)cc2-c3ccc(C(O)=O)[o]3)c2O)=NN1c1cc(CCC2)c2cc1 KRZYNXDIKJPGSW-QYQHSDTDSA-N 0.000 description 2
- LCFMHMLKNSJRNG-MKFPQRGTSA-N CC(C)(CC(C)(C)c1c2)c1ccc2N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c2cccc(C(O)=O)c2)c1O Chemical compound CC(C)(CC(C)(C)c1c2)c1ccc2N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c2cccc(C(O)=O)c2)c1O LCFMHMLKNSJRNG-MKFPQRGTSA-N 0.000 description 2
- WITKGWRONMFQRY-FAJYDZGRSA-N CC(C)(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c3ccc(C(O)=O)[s]3)c1O)c2 Chemical compound CC(C)(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c3ccc(C(O)=O)[s]3)c1O)c2 WITKGWRONMFQRY-FAJYDZGRSA-N 0.000 description 2
- JKHCSEPRRUKNJR-UHFFFAOYSA-N CC1(C)OB(c(cccc2[N+]([O-])=O)c2OC)OC1(C)C Chemical compound CC1(C)OB(c(cccc2[N+]([O-])=O)c2OC)OC1(C)C JKHCSEPRRUKNJR-UHFFFAOYSA-N 0.000 description 2
- SUNIZZCMZZNUJP-VJUDZZRDSA-N C/C(/C(O)=O)=C\C=C(\c(cccc1NC)c1O)/O Chemical compound C/C(/C(O)=O)=C\C=C(\c(cccc1NC)c1O)/O SUNIZZCMZZNUJP-VJUDZZRDSA-N 0.000 description 1
- IUMBFXVORWTHRY-QYQHSDTDSA-N CC(/C(/C1=O)=N/Nc(cccc2-c3c[s]c(C(O)=O)c3)c2O)=NN1c1cc(CCCC2)c2cc1 Chemical compound CC(/C(/C1=O)=N/Nc(cccc2-c3c[s]c(C(O)=O)c3)c2O)=NN1c1cc(CCCC2)c2cc1 IUMBFXVORWTHRY-QYQHSDTDSA-N 0.000 description 1
- ZJFGSTVAUPOMRT-QLYXXIJNSA-N CC(/C(/C1=O)=N/Nc2cccc(-c3ccc(C(O)=O)[o]3)c2O)=NN1c1cc(CCC2)c2cc1 Chemical compound CC(/C(/C1=O)=N/Nc2cccc(-c3ccc(C(O)=O)[o]3)c2O)=NN1c1cc(CCC2)c2cc1 ZJFGSTVAUPOMRT-QLYXXIJNSA-N 0.000 description 1
- BATIYVULRGAZAN-UHFFFAOYSA-N CC(C(C)=C1)(C2=CCC(C(O)=O)O2)C(OC)=C1[N+]([O-])=O Chemical compound CC(C(C)=C1)(C2=CCC(C(O)=O)O2)C(OC)=C1[N+]([O-])=O BATIYVULRGAZAN-UHFFFAOYSA-N 0.000 description 1
- SSJHCVPKVRRXNR-UHFFFAOYSA-N CC(C)(CC(C)(C)c1c2)c1ccc2N1N=C(C)CC1=O Chemical compound CC(C)(CC(C)(C)c1c2)c1ccc2N1N=C(C)CC1=O SSJHCVPKVRRXNR-UHFFFAOYSA-N 0.000 description 1
- HLSKTUANRGHHGI-UHFFFAOYSA-N CC(CC1=O)=NN1c1ccc(CCC2)c2c1 Chemical compound CC(CC1=O)=NN1c1ccc(CCC2)c2c1 HLSKTUANRGHHGI-UHFFFAOYSA-N 0.000 description 1
- AJNGYKJVXWONGA-UHFFFAOYSA-N CC(CC1=O)=NN1c1ccc(CCCC2)c2c1 Chemical compound CC(CC1=O)=NN1c1ccc(CCCC2)c2c1 AJNGYKJVXWONGA-UHFFFAOYSA-N 0.000 description 1
- JUPCUVIBHQVJRJ-SOFGYWHQSA-N CC/C(/c(cccc1N)c1O)=C\SCC(O)=O Chemical compound CC/C(/c(cccc1N)c1O)=C\SCC(O)=O JUPCUVIBHQVJRJ-SOFGYWHQSA-N 0.000 description 1
- DVNVHYZCRZPUIM-UHFFFAOYSA-N CC1(C)c2cc(N3N=C(C)CC3=O)ccc2CC1 Chemical compound CC1(C)c2cc(N3N=C(C)CC3=O)ccc2CC1 DVNVHYZCRZPUIM-UHFFFAOYSA-N 0.000 description 1
- SUGJWGQOVBOKGL-UHFFFAOYSA-N CC1OB(c2cc(C)cc([N+]([O-])=O)c2OC)OC1C Chemical compound CC1OB(c2cc(C)cc([N+]([O-])=O)c2OC)OC1C SUGJWGQOVBOKGL-UHFFFAOYSA-N 0.000 description 1
- CLSFJNMZEMHJON-UHFFFAOYSA-N CCC(CC1)c2c1ccc(N1N=C(C)CC1=O)c2 Chemical compound CCC(CC1)c2c1ccc(N1N=C(C)CC1=O)c2 CLSFJNMZEMHJON-UHFFFAOYSA-N 0.000 description 1
- WISYHTHFKZUFHN-ZXPTYKNPSA-N CCC1c2cc(N(C3=O)N=C(C)/C3=N/Nc(cc(C)cc3-c4cccc(C(O)=O)c4)c3O)ccc2CC1 Chemical compound CCC1c2cc(N(C3=O)N=C(C)/C3=N/Nc(cc(C)cc3-c4cccc(C(O)=O)c4)c3O)ccc2CC1 WISYHTHFKZUFHN-ZXPTYKNPSA-N 0.000 description 1
- NYZKGFJZUQAPJN-UHFFFAOYSA-N CNc1cccc(-c2ccc(C(O)=O)[o]2)c1OC Chemical compound CNc1cccc(-c2ccc(C(O)=O)[o]2)c1OC NYZKGFJZUQAPJN-UHFFFAOYSA-N 0.000 description 1
- OTKYHSQAWFYPNF-UHFFFAOYSA-N COc(c(N=O)ccc1)c1C(C1)=CSC1C(O)=O Chemical compound COc(c(N=O)ccc1)c1C(C1)=CSC1C(O)=O OTKYHSQAWFYPNF-UHFFFAOYSA-N 0.000 description 1
- BCUGMTSFLCYGEC-UHFFFAOYSA-N COc(c([N+]([O-])=O)ccc1)c1-c1ccc(C(O)=O)[o]1 Chemical compound COc(c([N+]([O-])=O)ccc1)c1-c1ccc(C(O)=O)[o]1 BCUGMTSFLCYGEC-UHFFFAOYSA-N 0.000 description 1
- UBNPVPHELUJSAP-UHFFFAOYSA-N Cc(cc1N)cc(-c2ccc(C(O)=O)[o]2)c1O Chemical compound Cc(cc1N)cc(-c2ccc(C(O)=O)[o]2)c1O UBNPVPHELUJSAP-UHFFFAOYSA-N 0.000 description 1
- GMBJMBHFEPCHRN-UHFFFAOYSA-N Cc(cc1N)cc(-c2ccc(C(O)=O)[o]2)c1OC Chemical compound Cc(cc1N)cc(-c2ccc(C(O)=O)[o]2)c1OC GMBJMBHFEPCHRN-UHFFFAOYSA-N 0.000 description 1
- LVQZRICCCFSHGG-UHFFFAOYSA-N Cc(cc1N)cc(-c2cccc(C(O)=O)c2)c1O Chemical compound Cc(cc1N)cc(-c2cccc(C(O)=O)c2)c1O LVQZRICCCFSHGG-UHFFFAOYSA-N 0.000 description 1
- UGRKXGRFPDDCFH-UHFFFAOYSA-N Cc(cc1N)cc(C2=CCC(C(O)=O)S2)c1O Chemical compound Cc(cc1N)cc(C2=CCC(C(O)=O)S2)c1O UGRKXGRFPDDCFH-UHFFFAOYSA-N 0.000 description 1
- VCSSKGYEGNNVAC-UHFFFAOYSA-N Cc(cc1NC)cc(-c2cc(C(O)=O)ccc2)c1O Chemical compound Cc(cc1NC)cc(-c2cc(C(O)=O)ccc2)c1O VCSSKGYEGNNVAC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810000346.6 | 2008-01-10 | ||
| CNA2008100003466A CN101481352A (zh) | 2008-01-10 | 2008-01-10 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
| PCT/CN2009/000001 WO2009092276A1 (zh) | 2008-01-10 | 2009-01-04 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011509263A JP2011509263A (ja) | 2011-03-24 |
| JP2011509263A5 JP2011509263A5 (https=) | 2012-02-23 |
| JP5441269B2 true JP5441269B2 (ja) | 2014-03-12 |
Family
ID=40878665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541680A Active JP5441269B2 (ja) | 2008-01-10 | 2009-01-04 | ビシクロ置換ピラゾロン−アゾ誘導体、その調製プロセス及び製薬学的使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8367710B2 (https=) |
| EP (1) | EP2236500B1 (https=) |
| JP (1) | JP5441269B2 (https=) |
| KR (1) | KR101556808B1 (https=) |
| CN (2) | CN101481352A (https=) |
| AU (1) | AU2009207966B2 (https=) |
| BR (1) | BRPI0907234B1 (https=) |
| CA (1) | CA2711535C (https=) |
| ES (1) | ES2533366T3 (https=) |
| MX (1) | MX2010007553A (https=) |
| PT (1) | PT2236500E (https=) |
| RU (1) | RU2488582C2 (https=) |
| UA (1) | UA101172C2 (https=) |
| WO (1) | WO2009092276A1 (https=) |
| ZA (1) | ZA201004794B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012529442A (ja) * | 2009-06-11 | 2012-11-22 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | ビシクロ置換ピラゾロン−アゾ誘導体の塩、その製造方法及びその使用 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| JP5704073B2 (ja) * | 2009-10-23 | 2015-04-22 | 日産化学工業株式会社 | 縮環へテロ環化合物及びトロンボポエチンレセプター活性化剤 |
| CN103360317B (zh) * | 2012-04-11 | 2016-12-14 | 齐鲁制药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及用途 |
| CN103724206A (zh) * | 2014-01-17 | 2014-04-16 | 青岛农业大学 | 化合物2-溴-4-氟-6-硝基苯酚的制备方法和农用生物活性 |
| WO2015111085A2 (en) * | 2014-01-27 | 2015-07-30 | Cadila Healthcare Limited | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof |
| US9849077B2 (en) | 2014-03-10 | 2017-12-26 | Mary Kay Inc. | Skin lightening compositions |
| CN104592033A (zh) * | 2014-12-30 | 2015-05-06 | 杭州和泽医药科技有限公司 | 一种艾曲波帕关键中间体的合成方法 |
| CN106994120B (zh) * | 2016-01-22 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
| TW201726129A (zh) * | 2016-01-22 | 2017-08-01 | 江蘇恆瑞醫藥股份有限公司 | 一種含有雙環取代吡唑酮偶氮類衍生物或其鹽的藥物組成物及其製備方法 |
| TWI762556B (zh) * | 2017-01-19 | 2022-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種雙環取代吡唑酮偶氮類衍生物的製備方法及其中間體 |
| CN110028497B (zh) * | 2018-01-11 | 2020-11-17 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法 |
| CN113226463A (zh) * | 2019-01-08 | 2021-08-06 | 江苏恒瑞医药股份有限公司 | 双环取代吡唑酮偶氮类衍生物的给药方案 |
| CN112062699B (zh) * | 2020-11-13 | 2021-02-26 | 苏州开元民生科技股份有限公司 | 一种邻氨基苯硫酚的制备方法 |
| WO2022228551A1 (zh) * | 2021-04-30 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素受体激动剂的给药方案 |
| US20250144077A1 (en) * | 2022-01-25 | 2025-05-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Dosage regimen for thrombopoietin receptor agonist |
| WO2025140275A1 (zh) * | 2023-12-25 | 2025-07-03 | 江苏恒瑞医药股份有限公司 | 取代吡唑啉偶氮衍生物的磷酸酯化合物或其可药用盐 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB775216A (en) * | 1954-02-23 | 1957-05-22 | Sandoz Ltd | Improvements in or relating to monoazo dyestuffs of the benzene-azo-pyrazolone series and their chromium-complex compounds |
| GB806709A (en) * | 1955-04-22 | 1958-12-31 | Bayer Ag | Monoazo dyestuffs of the benzene-azo-pyrazolone series and metal complexes thereof |
| TR199701526T1 (xx) | 1995-06-07 | 1998-03-21 | Glaxo Group Limited | Bir trombopoietin resept�r�ne ba�lanan peptitler ve bile�ikler. |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| JPH111477A (ja) | 1997-06-12 | 1999-01-06 | Hokuriku Seiyaku Co Ltd | １，４−ベンゾジアゼピン誘導体及びその用途 |
| AU9265698A (en) | 1997-09-02 | 1999-03-22 | Boehringer Mannheim Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing themand their use for the treatment and prevention of thrombocytopaenia and anaemia |
| JP2002529502A (ja) | 1998-11-17 | 2002-09-10 | スミスクライン・ビーチャム・コーポレイション | 血小板減少症の治療法 |
| WO2000039773A1 (de) | 1998-12-14 | 2000-07-06 | Mannesmann Ag | Verfahren zur übertragung von verkehrsinformationen |
| GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| KR20020069183A (ko) | 1999-07-26 | 2002-08-29 | 시오노기세이야쿠가부시키가이샤 | 트롬보포이에틴 작동성을 나타내는 의약 조성물 |
| EP1213965B1 (en) | 1999-09-10 | 2006-01-18 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| WO2001034585A1 (en) | 1999-11-05 | 2001-05-17 | Smithkline Beecham Corporation | Semicarbazone derivatives and their use as thrombopoietin mimetics |
| AU2079901A (en) | 1999-12-06 | 2001-06-12 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| CY2010012I2 (el) * | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| TWI280128B (en) * | 2002-05-22 | 2007-05-01 | Smithkline Beecham Corp | 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| EP2387998A1 (en) * | 2003-04-29 | 2011-11-23 | Glaxosmithkline LLC | Methods for treating degenerative diseases/injuries |
| DE602004019685D1 (de) | 2003-12-26 | 2009-04-09 | Allergan Inc | DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR |
| JP4518819B2 (ja) * | 2004-03-17 | 2010-08-04 | 富士フイルム株式会社 | アゾ化合物 |
| AU2005314788B2 (en) * | 2004-12-14 | 2011-09-22 | Nissan Chemical Industries, Ltd. | Amide compound and thrombopoietin receptor activator |
| JP2009511603A (ja) * | 2005-10-13 | 2009-03-19 | スミスクライン・ビーチャム・コーポレイション | 貯蔵中の血小板の有効性を維持する方法 |
| CA2630234A1 (en) * | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
-
2008
- 2008-01-10 CN CNA2008100003466A patent/CN101481352A/zh active Pending
-
2009
- 2009-01-04 ES ES09703490.4T patent/ES2533366T3/es active Active
- 2009-01-04 PT PT97034904T patent/PT2236500E/pt unknown
- 2009-01-04 WO PCT/CN2009/000001 patent/WO2009092276A1/zh not_active Ceased
- 2009-01-04 US US12/812,119 patent/US8367710B2/en active Active
- 2009-01-04 AU AU2009207966A patent/AU2009207966B2/en active Active
- 2009-01-04 CA CA2711535A patent/CA2711535C/en active Active
- 2009-01-04 CN CN2009800001980A patent/CN101679286B/zh active Active
- 2009-01-04 EP EP09703490.4A patent/EP2236500B1/en active Active
- 2009-01-04 MX MX2010007553A patent/MX2010007553A/es active IP Right Grant
- 2009-01-04 UA UAA201008616A patent/UA101172C2/ru unknown
- 2009-01-04 BR BRPI0907234-9A patent/BRPI0907234B1/pt active IP Right Grant
- 2009-01-04 KR KR1020107017630A patent/KR101556808B1/ko active Active
- 2009-01-04 JP JP2010541680A patent/JP5441269B2/ja active Active
- 2009-01-04 RU RU2010127786/04A patent/RU2488582C2/ru active
-
2010
- 2010-07-07 ZA ZA2010/04794A patent/ZA201004794B/en unknown
-
2013
- 2013-01-16 US US13/742,633 patent/US20130123507A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012529442A (ja) * | 2009-06-11 | 2012-11-22 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | ビシクロ置換ピラゾロン−アゾ誘導体の塩、その製造方法及びその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0907234B1 (pt) | 2021-08-10 |
| JP2011509263A (ja) | 2011-03-24 |
| PT2236500E (pt) | 2015-04-07 |
| RU2010127786A (ru) | 2012-02-20 |
| KR101556808B1 (ko) | 2015-10-01 |
| CA2711535C (en) | 2015-12-15 |
| BRPI0907234A2 (pt) | 2020-08-04 |
| KR20100120141A (ko) | 2010-11-12 |
| ES2533366T3 (es) | 2015-04-09 |
| CN101679286A (zh) | 2010-03-24 |
| US20100316601A1 (en) | 2010-12-16 |
| RU2488582C2 (ru) | 2013-07-27 |
| WO2009092276A1 (zh) | 2009-07-30 |
| EP2236500B1 (en) | 2014-12-24 |
| HK1134818A1 (en) | 2010-05-14 |
| AU2009207966A1 (en) | 2009-07-30 |
| MX2010007553A (es) | 2010-10-04 |
| EP2236500A1 (en) | 2010-10-06 |
| CA2711535A1 (en) | 2009-07-30 |
| CN101481352A (zh) | 2009-07-15 |
| EP2236500A4 (en) | 2012-08-22 |
| CN101679286B (zh) | 2011-06-08 |
| UA101172C2 (ru) | 2013-03-11 |
| US20130123507A1 (en) | 2013-05-16 |
| AU2009207966B2 (en) | 2013-03-21 |
| US8367710B2 (en) | 2013-02-05 |
| ZA201004794B (en) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5441269B2 (ja) | ビシクロ置換ピラゾロン−アゾ誘導体、その調製プロセス及び製薬学的使用 | |
| JP2011509263A5 (https=) | ||
| JP4546919B2 (ja) | トロンボポエチン摸倣物 | |
| JP5821079B2 (ja) | ビシクロ置換ピラゾロン−アゾ誘導体の塩、その製造方法及びその使用 | |
| AU2001274938A1 (en) | Thrombopoietin mimetics | |
| EP1244446A1 (en) | Thrombopoietin mimetics | |
| US6858630B2 (en) | Naphthimidazole derivatives and their use as thrombopoietin mimetics | |
| CN101679242B (zh) | 亚乙基肼酰胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2004527541A (ja) | トロンボポエチン模倣物 | |
| TWI437985B (zh) | 雙環取代吡唑酮偶氮類衍生物、其製備方法及其在醫藥上的應用 | |
| HK1134818B (en) | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof | |
| HK1117825B (en) | Thrombopoietin mimetics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111228 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130822 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130823 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131119 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131216 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131216 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5441269 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |